Statins, Cholesterol and Cognitive Decline in Alzheimer's

Karolinska Institute

Status: Completed

Conditions: Alzheimer Dementia; Statins

Treatments: Drug: STA 4783

Study type: Observational

Funder types: Other

Identifiers

NCT06635252

2024-00178-02

Details and patient eligibility

About

Disturbances in brain cholesterol homeostasis may be involved in the pathogenesis of Alzheimer's disease (AD). Lipid-lowering medications could interfere with neurodegenerative processes in AD through cholesterol metabolism or other mechanisms. The investigators aim to estimate the causal effect of statins on cognitive function measured by MMSE and to identify the mediating or modifying effect of cholesterol between statins and cognitive function in patients with Alzheimer's disease.

Enrollment: 2,000 patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

All patients with AD and mixed dementia registered in SveDem and from SCREAM.

Exclusion criteria

• All patients with a missing MMSE score at diagnosis date will be excluded from the analyses.
• Patients with at least one measurement of low-density lipoprotein cholesterol (LDL-C) within 1 year before dementia diagnosis.

Trial design

2,000 participants in 1 patient group

Patients with Alzheimer's disease

Description:

Prospective cohort study based on data from the Stockholm Creatinine Measurements (SCREAM) project. Patients diagnosed with AD and mixed dementia and registered in the Swedish Registry for Cognitive/Dementia Diseases are included.

Treatment:

Drug: STA 4783